 Good afternoon. My name is Laurent Selbiges. I'm a medical oncologist Currently working in Boston and previously with a burners could get and city Gustavo C so at the aim of the talk now is to focus on two major breakthrough in RCC biology in terms of Discovery and in treatment perspective perspective. So we'll have two different talks. We may start with the Q&A if they're available so Great. So this one is to introduce what Charlie Swanton is going to talk about The first is what about what are your thoughts in intratumor heterogeneity? Is it off no clinical relevance so far? Has it been appreciated for decades and what we have recently known is finally not so novel Is it restricted to kidney cancer only? does it explain the resistance to targeted therapy in my solid tumors and Does that mean does these findings means that we should stop efforts to develop further targeted therapy and Concentrate on immunotherapy that we are going to talk about afterwards Since these intratumor heterogeneity is relevant. I'll let you vote. We'll see if you have access to the answers or not We don't have music anymore Thank you. Okay, so answer four is that may explain resistance